-
FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
-
-
FILTER BY RELEVANCEMost Recent
-
-
FILTER BY CONTENT TYPEAll Content Types
-
Work – especially entrepreneurship – is viewed as an opportunity to author your own life, and large companies (and middle managers) are eager to grab hold of this concept, and this meme.
The question today is whether the innovation meme will soon require this sort of treatment – see this recent WSJ article, and this piece I wrote about the Successorization of Steve Jobs.
Almost everything you hear at graduations - and read on the internet, and watch on television - focuses on the idea of work, especially entrepreneurship, as a means of self-expression and (to use the term from David Brooks) self-actualization.
Roger Bate, author of the new book, “Phake: The Deadly World of Falsified and Substandard Medicines,” has found some incredibly realistic -- and deadly -- fake medicines. Which are real and which are phony? See if you can tell the difference.
Patients who take a close look at medical science in search of treatments are often appalled by what they discover. On the one hand, there's academic research, a self-contained and self-absorbed universe of its own where data may be internally consistent (on a good day) and robustly reproducible, yet often has little relevance to real-world clinical conditions.
American Enterprise Institute (AEI) scholar Scott Gottlieb, MD a former senior adviser to the Center for Medicare and Medicaid Services (CMS) warns that a new ruling by CMS will force people to get open-heart surgeries that might have been avoidable.
In a just-published op-ed in the New York Times, American Enterprise Institute (AEI) international health economist Roger Bate highlights a better way to fight fake pharmaceuticals while still giving poor Americans access to less costly drugs from online pharmacies.
Knowing where all our ingredients come from is the first step toward improving drug quality.
Today, URL Pharma was acquired by Takeda for nearly $800M. The story here in brief is that for hundreds of years, colchicine was used for the treatment of gout and other conditions; it was an effective drug but had to be used carefully. URL invested in the formulation development and clinical studies required for colchicine, and ultimately received FDA approval in 2009.




